Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Développement économique,
Santé
|
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
|
Proposition législative, Projet de loi ou résolution,
Règlement
|
Santé
|
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
|
Politique ou Programme
|
Santé
|
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
|
Politique ou Programme
|
Développement économique,
Santé
|
To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
|
Politique ou Programme
|
Développement économique,
Santé
|
To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
|
Politique ou Programme
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Organon Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including biosimilar drugs and women’s health products, which are the company’s main sectors of activities.
|
Proposition législative, Projet de loi ou résolution,
Règlement
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of Organon's products.
|
Politique ou Programme
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Representations relating to the conditions under which biosimilar drugs are marketed and reimbursed in Canada. More specifically, representations are made to support a favorable and knowledgeable environment to implement new or improve current women’s health programs, the integration of biosimilar drugs into the drug plans administered by the Federal Government and to emphasize the importance that the federal government respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs.
|
Politique ou Programme
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
To actively promote the enhancement of publicly funded women’s health initiatives and programs, including the development of a Pan Canadian Women’s Health Strategy.
|
Politique ou Programme
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
To actively promote the value of the pharmaceutical industry for Canada's economic health and well being, but more importantly for the health and well being of its citizens and to propose solutions for integrated health care in Canada.
|
Politique ou Programme
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
To recommend policies that will attract increased investment in the pharmaceutical and well being industry, such as on policies, research programs and policies and the Innovation Agenda.
|
Politique ou Programme
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: